


PHARMACEUTICAL 2020

RespireRx Pharmaceuticals Inc. Rank 283 of 362







PHARMACEUTICAL 2020

RespireRx Pharmaceuticals Inc. Rank 283 of 362

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 1,761% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 162% points.

The company's Economic Capital Ratio, given in the ranking table, is -445%, being 142% points below the market average of -303%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 45 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 7,490 |
| Liabilities, Non-Current | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 0 |
| Other Expenses | 405 |
| Other Liabilities | 0 |
| Other Net Income | 26 |
| Property and Equipment | 0 |
| Research and Development | 599 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 1,137 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 45 |
| Liabilities | 7,490 |
| Expenses | 2,141 |
| Stockholders Equity | -7,445 |
| Net Income | -2,115 |
| Comprehensive Net Income | -2,115 |
| Economic Capital Ratio | -445% |

